[go: up one dir, main page]

MX2013006591A - Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas. - Google Patents

Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.

Info

Publication number
MX2013006591A
MX2013006591A MX2013006591A MX2013006591A MX2013006591A MX 2013006591 A MX2013006591 A MX 2013006591A MX 2013006591 A MX2013006591 A MX 2013006591A MX 2013006591 A MX2013006591 A MX 2013006591A MX 2013006591 A MX2013006591 A MX 2013006591A
Authority
MX
Mexico
Prior art keywords
dosage forms
controlled release
oral dosage
poorly soluble
release oral
Prior art date
Application number
MX2013006591A
Other languages
English (en)
Other versions
MX354210B (es
Inventor
Ming J Chen
Ho-Wah Hui
Xiaole Shen
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45930969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013006591(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2013006591A publication Critical patent/MX2013006591A/es
Publication of MX354210B publication Critical patent/MX354210B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se proporcionan las formas farmacéuticas orales de liberación controlada de fármacos escasamente solubles, los métodos para preparar las formas farmacéuticas, y los métodos para su uso en el tratamiento de diversas enfermedades y/o trastornos.
MX2013006591A 2010-12-16 2011-12-15 Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas. MX354210B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42400310P 2010-12-16 2010-12-16
PCT/US2011/065151 WO2012083017A2 (en) 2010-12-16 2011-12-15 Controlled release oral dosage forms of poorly soluble drugs and uses thereof

Publications (2)

Publication Number Publication Date
MX2013006591A true MX2013006591A (es) 2013-11-04
MX354210B MX354210B (es) 2018-02-16

Family

ID=45930969

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006591A MX354210B (es) 2010-12-16 2011-12-15 Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.

Country Status (8)

Country Link
US (1) US20140018404A1 (es)
EP (1) EP2651400B2 (es)
JP (1) JP6143675B2 (es)
CN (1) CN103442698B (es)
CA (1) CA2821805A1 (es)
ES (1) ES2753198T5 (es)
MX (1) MX354210B (es)
WO (1) WO2012083017A2 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2853829C (en) 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
FI3756650T3 (fi) * 2011-12-27 2025-10-30 Amgen Europe Gmbh (+)-2-[1-(3-etoksi-4-metoksifenyyli)-2-metaanisulfonyylietyyli]-4-asetyyliaminoisoindoliini-1,3-dionin formulaatioita
EP2730278A1 (en) * 2012-11-08 2014-05-14 Ratiopharm GmbH Composition melt
EP3010490A1 (en) * 2013-06-17 2016-04-27 Celgene Corporation Tablet formulations of (+)-2-[1 -(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
EP3066201B1 (en) 2013-11-07 2018-03-07 Editas Medicine, Inc. Crispr-related methods and compositions with governing grnas
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
WO2015173792A1 (en) * 2014-05-11 2015-11-19 Mapi Pharma Ltd. Amorphous form of apremilast
CA2956224A1 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
EP4434997A3 (en) 2014-10-30 2025-01-01 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
CN113559075A (zh) 2014-11-17 2021-10-29 康泰科思特生物制药公司 奥那司酮延长释放组合物和方法
AU2015361122B2 (en) 2014-12-10 2020-12-17 Elevate Oral Care, Llc Composition for the relief of dry mouth
CN104529869B (zh) * 2014-12-19 2017-06-13 苏州亚宝药物研发有限公司 一种 (s)‑2‑[1‑(3‑乙氧基‑4‑甲氧基苯基)‑2‑甲磺酰基乙基]‑4‑乙酰基氨基异吲哚啉‑1,3‑二酮异构体的制备方法
WO2016135755A1 (en) * 2015-02-27 2016-09-01 Mylan Laboratories Limited Amorphous apremilast, premixes thereof, and novel crystalline forms of apremilast
BR112018005999A2 (pt) 2015-09-25 2019-01-08 Context Biopharma Inc métodos para a produção de intermediários de onapristona
CN105218428A (zh) * 2015-10-20 2016-01-06 南京美嘉宁逸医药研究开发有限公司 一种高手性纯度的阿普斯特的制备方法
AU2016342380B2 (en) 2015-10-23 2022-04-07 President And Fellows Of Harvard College Nucleobase editors and uses thereof
CN105343025A (zh) * 2015-11-08 2016-02-24 长沙佰顺生物科技有限公司 一种阿普斯特口服制剂及其制备方法
EP3373916A1 (en) * 2015-11-11 2018-09-19 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
KR20180113988A (ko) 2015-12-15 2018-10-17 컨텍스트 바이오파마 인코포레이티드 비정질 오나프리스톤 조성물 및 그 제조방법
JP2019501207A (ja) * 2016-01-08 2019-01-17 シーティーシー バイオ，インコーポレイテッド バレニクリンまたはこの薬学的に許容可能な塩を含有する、味の遮蔽された口腔投与用薬学製剤
IL308426B1 (en) 2016-08-03 2025-11-01 Harvard College Adenosine nucleobase editors and uses thereof
JP7201153B2 (ja) 2016-08-09 2023-01-10 プレジデント アンド フェローズ オブ ハーバード カレッジ プログラム可能ｃａｓ９－リコンビナーゼ融合タンパク質およびその使用
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
KR20200121782A (ko) 2017-10-16 2020-10-26 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
EP3797160A1 (en) 2018-05-23 2021-03-31 The Broad Institute Inc. Base editors and uses thereof
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
BR112021004670A2 (pt) 2018-09-28 2021-06-01 President And Fellows Of Harvard College reprogramação celular para reverter o envelhecimento e promover a regeneração de órgãos e tecidos
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
DE112020001342T5 (de) 2019-03-19 2022-01-13 President and Fellows of Harvard College Verfahren und Zusammensetzungen zum Editing von Nukleotidsequenzen
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
EP4146804A1 (en) 2020-05-08 2023-03-15 The Broad Institute Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
CN111728949B (zh) 2020-07-17 2022-10-04 广州帝奇医药技术有限公司 一种难溶性药物口服缓释组合物及其制备方法
AU2021391823A1 (en) 2020-12-03 2023-06-29 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
CA3216359A1 (en) 2021-04-07 2022-10-13 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2023118043A1 (en) * 2021-12-22 2023-06-29 Biohorm, S.L. Pharmaceutical compositions of apremilast
EP4504232A1 (en) 2022-04-06 2025-02-12 President and Fellows of Harvard College Reversing aging of the central nervous system
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
DE3686275T2 (de) * 1985-01-11 1993-03-18 Teijin Ltd Praeparate mit verzoegerter freisetzung.
US4915952A (en) 1987-02-27 1990-04-10 Alza Corporation Composition comprising drug, HPC, HPMC and PEO
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5451409A (en) 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5705190A (en) 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6251430B1 (en) * 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
JP2003521507A (ja) 2000-02-04 2003-07-15 ディポメド，インコーポレイティド ゼロ次薬物放出に接近するシェル−コア剤形
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US20040087558A1 (en) 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
EP1605896B1 (en) * 2003-03-12 2013-09-18 Celgene Corporation 7-amino- isoindolyl compounds amd their pharmaceutical uses
KR20070092276A (ko) 2004-12-13 2007-09-12 셀진 코포레이션 Ｐｄｅ４ 조절인자를 포함하는 조성물 및 이의 기도염의치료 또는 예방을 위한 용도
AU2006212021B2 (en) * 2005-02-10 2010-09-30 Orexo Ab Pharmaceutical compositions useful in the transmucosal administration of drugs
US20070155791A1 (en) 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
CN101011393B (zh) * 2007-02-16 2010-10-06 广州柏赛罗药业有限公司 厄贝沙坦胃内滞留型缓释药物组合物
DE102007026037A1 (de) 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentives System mit Alginat-Körper
WO2009120617A2 (en) 2008-03-24 2009-10-01 Jda Software, Inc. Linking discrete dimensions to enhance dimensional analysis
HRP20140609T1 (hr) * 2008-03-27 2014-08-15 Celgene Corporation Äśvrsti oblici koji sadrže (+)-2-[1-(3-etoksi-4-metoksifenil)-2-metilsulfoniletil]-4-acetilaminoizoindolin-1,3-dion, njegovi pripravci i njihova upotreba
PL2334639T3 (pl) 2008-09-10 2013-08-30 Celgene Corp Sposoby wytwarzania związków aminosulfonowych
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
AU2010213936B2 (en) 2009-02-10 2014-07-31 Celgene Corporation Methods of using and compositions comprising PDE4 modulators for treatment, prevention and management of tuberculosis
CN101700235A (zh) * 2009-11-24 2010-05-05 沈阳药科大学 自组装复合物膜控缓释制剂及其制备方法

Also Published As

Publication number Publication date
EP2651400B2 (en) 2023-01-18
MX354210B (es) 2018-02-16
CN103442698B (zh) 2016-10-05
WO2012083017A2 (en) 2012-06-21
ES2753198T5 (es) 2023-05-31
ES2753198T3 (es) 2020-04-07
JP2013545814A (ja) 2013-12-26
US20140018404A1 (en) 2014-01-16
JP6143675B2 (ja) 2017-06-07
WO2012083017A3 (en) 2012-08-23
CA2821805A1 (en) 2012-06-21
EP2651400B1 (en) 2019-08-07
EP2651400A2 (en) 2013-10-23
CN103442698A (zh) 2013-12-11

Similar Documents

Publication Publication Date Title
MX354210B (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
ZA202004764B (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
MX2014004862A (es) Formulaciones de polimero acrilico.
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2012001974A (es) Compuestos de biarilo y metodos de uso de los mismos.
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
AU2013299841A8 (en) Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
IL217467A (en) Derivatives of aminopyridine for the treatment of tumors, inflammatory diseases and their use
WO2013052647A3 (en) Formulations and uses of retinoic acid receptor selective agonists
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
WO2012100043A3 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
PH12012501389A1 (en) Hedgehog inhibitors
MX347105B (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
WO2011150201A3 (en) Azolyl amide compounds and methods of use thereof
PH12015500823A1 (en) Modified release formulations for oprozomib
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
UA112488C2 (uk) Три(гетеро)арилпіразоли і їх застосування
MX2013007959A (es) Formas farmaceuticas orales de amida {2-[(1s)-1-(3-etoxi-4-metoxi- fenil]-2-metansulfonil-etil]-3-oxo-2,,3-dihidro-1h-isoindol -4-il}-del acido ciclopropancarboxilico.
MY148088A (en) Stable nanoparticle formulations
UA60150U (ru) Способ медицинской реабилитации женщин с рецидивирующей формой генитального герпеса

Legal Events

Date Code Title Description
GD Licence granted
FG Grant or registration